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Drug discovery for malaria has been transformed in the last 5
years by the discovery of many new lead compounds identified by
phenotypic screening. The process of developing these com-
pounds as drug leads and studying the cellular responses they
induce is revealing new targets that regulate key processes in the
Plasmodium parasites that cause malaria. We disclose herein that
the clinical candidate (+)-SJ733 acts upon one of these targets,
ATP4. ATP4 is thought to be a cation-transporting ATPase respon-
sible for maintaining low intracellular Na+ levels in the parasite.
Treatment of parasitized erythrocytes with (+)-SJ733 in vitro
caused a rapid perturbation of Na+ homeostasis in the parasite.
This perturbation was followed by profound physical changes in
the infected cells, including increased membrane rigidity and ex-
ternalization of phosphatidylserine, consistent with eryptosis
(erythrocyte suicide) or senescence. These changes are proposed
to underpin the rapid (+)-SJ733-induced clearance of parasites
seen in vivo. Plasmodium falciparum ATPase 4 (pfatp4) mutations
that confer resistance to (+)-SJ733 carry a high fitness cost. The
speed with which (+)-SJ733 kills parasites and the high fitness cost
associated with resistance-conferring mutations appear to slow
and suppress the selection of highly drug-resistant mutants in
vivo. Together, our data suggest that inhibitors of PfATP4 have
highly attractive features for fast-acting antimalarials to be used in
the global eradication campaign.
malaria | PfATP4 | drug discovery
In 2010, there were 220 million cases of malaria, leading to660,000 deaths. More than 400,000 of those who died were
African children (1). Recent successes in antimalarial drug dis-
covery and development have led to renewed hope for global
eradication of malaria (2, 3). Antimalarial drugs are a critical
component of the eradication campaign, and single-dose regi-
mens of cheap, safe, and efficacious drugs, which ideally also
reduce transmission, are required (4). The discovery of agents
that act rapidly against novel targets would greatly aid in the
development of such drugs (5). Additionally, given the ready
propensity with which the parasite develops resistance to new
antimalarials (6), targets for which drug-resistance–conferring
mutations cause a high fitness cost are of particular interest.
In a high-throughput screen to identify molecules that block
the proliferation of Plasmodium falciparum in cocultures with
human erythrocytes in vitro, we identified three high-priority
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Useful antimalarial drugs must be rapidly acting, highly effica-
cious, and have low potential for developing resistance. (+)-SJ733
targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733
cleared parasites in vivo as quickly as artesunate by specifically
inducing eryptosis/senescence in infected, treated erythrocytes.
Although in vitro selection of pfatp4 mutants with (+)-SJ733
proceeded with moderate frequency, during in vivo selection of
pbatp4 mutants, resistance emerged slowly and produced mar-
ginally resistant mutants with poor fitness. In addition, (+)-SJ733
met all other criteria for a clinical candidate, including high oral
bioavailability, a high safety margin, and transmission blocking
activity. These results demonstrate that targeting ATP4 has great
potential to deliver useful drugs for malaria eradication.
Author contributions: M.B.J.-D., A.M.L., K.G.O., A.S.M.D., W.A.G., C.C.K., L.S., N.J.S., P.D.S., F.Z.,
V.M.A., D.A.F., F.-J.G., S.A.C., J.C.M., H.M., S.F., K.K., I.A.-B., D.E.K., J.L.D., D.M.F., and R.K.G.
designed research; M.B.J.-D., D.E., Y.S., A.P., A.M.L., M.-E.M.-L., K.G.O., D.M.S., M.J.d.A.,
A.K.C., J.A.C., A.S.M.D., J.D., X.D., S.D., A.N.E., G.F., W.A.G., M.G.G., G.H., J.H., C.C.K., J.L.,
M.C.S.L., A.M., M.S.M., A.R.-A., L.S., M.S., N.J.S., P.D.S., Z.W., F.Z., and J.L.D. performed research;
J.L.D. contributed new reagents/analytic tools; M.B.J.-D., D.E., Y.S., A.P., A.M.L., K.G.O., D.M.S.,
J.A.C., A.S.M.D., A.N.E., W.A.G., M.G.G., G.H., C.C.K., J.L., M.C.S.L., M.S.M., G.M., L.S., N.J.S., P.D.S.,
F.Z., D.W., S.K., A.S., V.M.A., D.A.F., F.-J.G., S.A.C., J.C.M., H.M., S.F., K.K., I.A.-B., D.E.K., J.L.D.,
D.M.F., and R.K.G. analyzed data; and D.A.F., K.K., D.E.K., J.L.D., and R.K.G. wrote the paper.
Conflict of interest statement: M.B.J.-D., M.G.G., M.S.M., A.R.-A., L.S., F-J.G., S.F., and I.A.-B. are
employees of GlaxoSmithKline and are engaged in commercial development of antimalarial
drugs, although not this compound.
*This Direct Submission article had a prearranged editor.
Data deposition: The sequencing data have been deposited in the National Center for
Biotechnology Information BioProject database, www.ncbi.nlm.nih.gov/bioproject (pro-
ject ID PRJNA253899).
1To whom correspondence should be addressed. Email: kip.guy@stjude.org.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1414221111/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1414221111 PNAS | Published online December 1, 2014 | E5455–E5462
PH
A
RM
A
CO
LO
G
Y
PN
A
S
PL
U
S
series (7). Pharmacological and chemical optimization of one
of these series, the dihydroisoquinolones (DHIQs), led to the
selection of a clinical candidate, (+)-SJ733, for development as
a fast clearance component (Target Candidate Profile 1; TCP1)
of a single-exposure radical cure and prophylaxis (SERCaP) drug
(4). Here, we present evidence that (+)-SJ733 acts on the re-
cently recognized target PfATP4 (pfatp4; PFL0590c) (8) to give
rapid clearance of the parasite in vivo by inducing eryptosis or
senescence in parasite-infected erythrocytes. Mutation of pfatp4
to confer resistance to (+)-SJ733 carries a high fitness cost, and
the development of resistance in vivo is slow and produces only
low-level resistance.
Results and Discussion
(+)-SJ733 Is a Candidate for TCP1 of a SERCaP Drug. SJ733 was highly
potent in vitro against all tested strains of P. falciparum (EC50
range 10–60 nM; SI Appendix, Fig. S1A and Table S1), including
those resistant to other antimalarials, and was equally potent
against all stages of the erythrocytic life cycle (SI Appendix, Fig.
S3E). Of the two enantiomers of SJ733, the (+)-enantiomer was
significantly more potent. (+)-SJ733 was, however, 10-fold less
potent against Plasmodium berghei and other rodent malarias ex
vivo (SI Appendix, Fig. S1B). (+)-SJ733 bound to a single re-
ceptor site in P. falciparum-infected erythrocytes with equivalent
affinity to its growth-inhibitory potency (kd = 50 nM; SI Ap-
pendix, Fig. S3F).
(+)-SJ733 was highly potent and efficacious against P. falciparum
3D70087/N9 in vivo when administered as four sequential daily oral
doses in the NOD-scid IL2Rγnull mouse model (Fig. 1A) (9), with
a 90% effective dose, (ED90 1.9 mg/kg) and exposure [area under
the curve at ED90 (AUCED90), 1.5 μM·h] superior to artesunate
(11.1 mg/kg; AUCED90 not determined), chloroquine (4.3 mg/kg;
AUCED90 3.1 μM·h), and pyrimethamine (0.9 mg/kg; AUCED90
5. μM·h) in the same model. When treated with the ED90 dose,
(+)-SJ733 concentrations in blood remained above the average
in vitro EC90 for 6–10 h after each dose (SI Appendix, Fig. S1C).
In line with ex vivo results, SJ733 was 10-fold less potent in vivo
against P. berghei when administered as four sequential daily oral
doses (racemate ED90 40 mg/kg; AUCED90 80 μM·h; SI Appendix,
Fig. S1D), with (r)-SJ733 concentrations in blood remaining above
the average ex vivo EC90 for 10–12 h after each dose (SI Appendix,
Fig. S1E). (+)-SJ733 had robust in vivo pharmacokinetic be-
havior in all preclinical species, including mouse, rat, and dog,
with excellent exposure (3–10 μM Cmax, 5–40 μM–h AUC, at 20–
30 mg/kg doses) and reasonable clearance (Fig. 1B). The com-
pound also had oral bioavailability of >65% in both rats (SI
Appendix, Fig. S1F) and dogs (SI Appendix, Fig. S1G).
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Fig. 1. SJ733 is an efficacious and safe orally active drug candidate. (A) SJ733 is efficacious against P. falciparum 3D70087/N9 in the nonobese diabetic Scid
interleukin-2 receptor γ chain null (NSG) mouse model with the (+)-enantiomer exhibiting excellent potency (1.9 mg/kg); similar to pyrimethamine (ED90
0.9 mg/kg) and superior to chloroquine (ED90 4.3 mg/kg) in this model. (+)-SJ733 achieves this efficacy from exposure (AUCED90 1.5 μM·h) similar to that of
chloroquine (AUCED90 3.1 μM·h) and superior to that of pyrimethamine (AUCED90 5.2 μM·h) in the same model. (B) (+)-SJ733 exhibits excellent exposure after oral
administration in mouse, rat, and dog. In rodents, (+)-SJ733 reaches peak plasma concentrations of ∼5 μM within 1 h after 20–25 mg/kg doses and >20 μM in dogs
following a 30 mg/kg oral dose. (C) (+)-SJ733 exhibits no significant toxicology at doses up to 200 mg/kg in rats with an exposure (AUC) ∼43-fold higher than that
required to produce the maximum parasitological response (fastest rate of killing) and 220-fold that required to produce the ED90 in the mouse, indicating the
potential for an excellent therapeutic ratio. (D) (+)-SJ733 potently and efficaciously blocks transmission of P. berghei from infected mice to mosquitos when themice
are treated 1 h before feeding the mosquitos as measured by counting oocysts from dissected mosquitos after the sexual stage is allowed to mature.
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(+)-SJ733 has not exhibited either significant safety liabilities
at any dose in extensive profiling in vitro (see summary in SI
Appendix) or significant safety or tolerability liabilities in either
single- or repeat-dose studies at any dose tested in any preclinical
species (no observed adverse effect level and maximum tolerated
dose >240 mg/kg from 7-d repeat dosing study in rat; see sum-
mary in SI Appendix). Therefore, (+)-SJ733 is expected to have
a safety margin of at least 43-fold [comparing AUCmax in the rat
safety studies to AUC from the dose giving maximal parasitolog-
ical response in mice (Fig. 1C)]. In addition, (+)-SJ733 blocked
transmission of P. berghei from infected mice to mosquitos (ED50
5 mg/kg; Fig. 1D), at a dose lower than that efficacious against
asexual blood stages. Finally, (+)-SJ733 was readily synthesized in
good yield from commercially available precursors in five steps
with a route that is expected to provide low cost of goods (SI
Appendix, Fig. S1H). The only potential liability noted to date was
a relatively high clearance in human microsomal models (SI Ap-
pendix). However, predicted efficacious human doses, allometri-
cally derived from preclinical pharmacokinetics experiments, fall
into the range of 3–6 mg/kg, and the projected half-life is long
enough to allow (+)-SJ733 to be the fast acting component
(TCP1) of a SERCaP drug (4). Thus, (+)-SJ733 is highly potent,
efficacious against both asexual and sexual blood stages, safe, and
highly orally bioavailable. (+)-SJ733 was selected for clinical de-
velopment by Medicines for Malaria Venture in March 2013.
(+)-SJ733 Targets ATP4.To gain insight into the mechanism of action
of (+)-SJ733 and the potential for acquisition of resistance, we se-
lected drug-resistant mutant strains of P. falciparum in vitro and
P. berghei in vivo, using (+)-SJ733 and other DHIQ analogs, and
characterized the alleles conferring resistance (6, 10). Mutant
strains were generated in vitro by pressuring erythrocytic cocultures
with (+)-SJ733 or other DHIQ analogs (SI Appendix, SI Materials
and Methods) until apparently resistant parasites emerged. Re-
sistance, confirmed by measuring the potency of (+)-SJ733, varied
between twofold to ∼750-fold (SI Appendix, Table S1) and emerged
with minimum inocula of between 107 and 109 parasites (3D7
strain). In most cases, resistance was ∼10-fold and emerged from
108 to 109 parasites (SI Appendix, Fig. S2A). The single mutant
strain generated in vivo was produced by serial passage of parasites
in mice with multiple rounds of intermittent high-dose treatment
with (+)-SJ311, a close analog of (+)-SJ733 (SI Appendix, Fig. S2C),
with weak (twofold) stable resistance emerging only after 4 weeks
of treatment.
For six independently produced resistant P. falciparum strains,
we used whole-genome sequencing to identify mutations (SI
Appendix, Table S2). Genomic DNA was prepared for parental
and mutant strains, and libraries were sequenced (SI Appendix).
After quality filtering and alignment to the reference sequence,
the average coverage ranged from >50-fold to >700-fold for the
14 nuclear chromosomes and >200-fold to >30,000-fold for the
mitochondrial and plastid genomes. The presence of copy
number variants (CNVs) was assessed, relative to the parental
strains, by using the R-package CNV-Seq (11). Other than the
variable sequences proximal to the telomeres, no significant (P <
0.001) deletions were detected relative to the drug-sensitive pa-
rental strains (SI Appendix, Table S3). Similarly, no amplified
regions were detected for any strain. To detect genomic muta-
tions we compared exonic sequences for both the parental and
selected strains. Because the mutant strains were not necessarily
clonal populations, we reasoned that true drivers of drug re-
sistance would be gain-of-function mutations driven to purifica-
tion as opposed to passenger mutations present at various
frequencies. Therefore, we considered only nonsynonymous
mutations that were present at 99% purity or higher, where
purity was defined as the percent of the total reads confirming
a mutation for a given position in the genome, assuming that
mutations occurred in single-copy genes.
By using these criteria, only a single mutated gene, encoding the
putative Na+-ATPase PfATP4 (PFL0590c), was shared among all
six selections (SI Appendix, Table S2). In five of six selections,
100% of the mapped reads confirmed the detected mutation, all
of which were confirmed by Sanger sequencing. In five of six
strains, pfatp4 was the only mutated gene detected using these
criteria. We also investigated whether expression of the mRNA
for pfatp4, as measured by quantitative RT-PCR (qRT-PCR), was
altered in wild-type or mutated strains, with or without treatment
with (+)-SJ733. Relative to a housekeeping gene, we detected no
significant change in expression (SI Appendix, Table S4).
Two additional independently derived resistant strains were
generated by selection with SJ733 or another DHIQ. Sanger se-
quencing of the pfatp4 coding sequence identified nonsynonymous
mutations in both cases (SI Appendix, Table S3). For the sole
resistant P. berghei strain , described above, sequencing of the
orthologous gene pbatp4 revealed a nonsynonymous mutation
absent in parental parasites (SI Appendix, Table S5).
Finally, we examined whether cross-resistance existed for mutant
strains of malaria previously selected with other putative PfATP4
targeted compounds, including the DHIQ family, the spiroindolones,
and a series developed at GlaxoSmithKline (SI Appendix, Table S5).
In all cases there was complete and bidirectional cross-resistance for
all compounds and strains (SI Appendix, Table S1). The fold
resistance exhibited by each strain tracked with the genotype
and was consistent from compound to compound. This finding
strongly suggests that the mutation(s) in pfatp4 are the sole
determinant of resistance for each of the compounds.
Two DHIQ-resistant mutant strains (P. falciparumATP4L350H
and ATP4P966T) were tested in competition assays and were
found to be substantially less fit than their parental strains in the
absence of drug pressure (SI Appendix, Fig. S2B). The slow
emergence of DHIQ resistance observed during our in vivo se-
lection experiment is consistent with our finding of a fitness cost
associated with DHIQ resistance.
Together, the complete association of resistance with point
mutations in pfatp4, the absence of copy-number variations or
expression-level differences for this gene, and the cross-resistance
with spiroindolones all support the notion that mutation of
PfATP4 is both necessary and sufficient for resistance to SJ733.
A homology model for PfATP4, built from crystal structures of
the closest mammalian homolog (sarco/endoplasmic reticulum
Ca2+-ATPase; SERCA), revealed that the majority of the
resistance-conferring mutations clustered in a small portion of
the predicted protein structure within the transmembrane, ion-
transporting channel of the protein (Fig. 2 A and C). All other
resistance-conferring mutations were predicted to perturb the
protein structure near this cluster by distorting the orientation of
helices adjoining the cluster. Unconstrained docking of the
structure of (+)-SJ733 to this homology model revealed one
predicted binding site, which is enveloped by the cluster of res-
idues bearing resistance-conferring mutations (Fig. 2B).
The three rodent malaria species (P. berghei, Plasmodium
vinckei, and Plasmodium chabaudi) were all significantly less
sensitive to (+)-SJ733 than was P. falciparum both ex vivo (SI
Appendix, Fig. S1B) and in vivo (SI Appendix, Figs. S1D and S2D).
The atp4 alleles from these species carry a short variant sequence
(SI Appendix, Fig. S2E), which is predicted to encode a loop within
the (+)-SJ733 binding site (purple ribbon, Fig. 2B). Replacing the
pbatp4 gene with the pfatp4 gene fully conferred increased sus-
ceptibility to (+)-SJ733 ex vivo (SI Appendix, Fig. S1B) and par-
tially (2-fold vs. 10-fold) restored sensitivity in vivo (SI Appendix,
Figs. S1D and S2D), thus strongly suggesting that the sequence
variations underpin the reduced susceptibility of the rodent
malarias to (+)-SJ733. The lack of a full restoration of sensitivity
in vivo may be due to differences between the humanized mouse
model used for P. falciparum and the normal mouse model used
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for P. berghei, but is not driven by differing pharmacokinetics,
because there were no significant exposure variations.
PfATP4 has been proposed to be a Na+-efflux ATPase that
maintains a low Na+ concentration in the parasite cytosol ([Na+]i)
(12). As with the spiroindolones (12), treatment of saponin-
isolated trophozoites with (+)-SJ733 resulted in a rapid increase in
[Na+]i from a resting level of 6 ± 1 mM to a maximal level of 110 ±
10 mM within ∼1.5 h of initiating treatment (Fig. 2D and SI
Appendix, Fig. S2F). As is also seen for the spiroindolones (13),
(+)-SJ733 caused a rapid increase in the transmembrane pH
gradient (0.11 ± 0.03 pH units; mean ± SD n = 6) and reduced
the extent of acidification of the parasite cytosol seen following
the inhibition of the parasite’s plasma membrane V-type H+
ATPase by concanamycin A (SI Appendix, Fig. S2G).
The EC50 for the effect of (+)-SJ733 on [Na
+]i in wild-type
parasites is ∼200 nM, within fivefold of the growth inhibition
potency in the same strain (SI Appendix, Fig. S1A) and well
within the concentrations achieved in the blood of effectively
treated animals (SI Appendix, Fig. S1C). The P. falciparum
ATP4L350H strain, which is resistant to (+)-SJ733, showed a
∼50-fold decrease in sensitivity (relative to the parental strain) to
the [Na+]i-disrupting effects of (+)-SJ733. Furthermore, the
relative potency of the enantiomers of SJ733 in the [Na+]i assays
for these strains was the same as in the proliferation assays (Fig.
2D and SI Appendix, Fig. S1A). The mutant strain had a signifi-
cantly higher resting [Na+]i than the parent (15.8 ± 0.8 mM vs.
5.7 ± 0.5 mM; mean ± SEM from 9 or 10 independent experi-
ments; P < 0.001 with unpaired t test), which may account for the
decreased fitness of this strain. The data are consistent with the
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Fig. 2. SJ733 targets the PfATP4 protein. (A) All SJ733-resistant strains of malaria generated worldwide contain mutations in the pfatp4 gene that cluster in
a single region of the protein. The mutations are illustrated with a homology model of the protein structure for PfATP4 (gold/blue ribbon), built from the
available SERCA crystal structures, with the location of mutations causing either high-fold resistance (red), medium-fold resistance (yellow), or low-fold
resistance (blue) shown as solid fill. The blue helices represent those in the transmembrane domain and are indicated in the gene block diagram in C. (B)
Theoretical docking studies with (+)-SJ733 reproducibly generate a single pose that places (+)-SJ733 in contact with the two residues inducing the highest fold
resistance and the one residue selected by in vivo passage with cycling drug exposure. This pose is illustrated by the docked structure of (+)-SJ733 placed into
the putative binding site on the PfATP4 structure, with residues conferring resistance color-coded as in A. A loop with sequence variability among Plasmodium
spp. that may lead to differing sensitivities to (+)-SJ733 is highlighted in magenta. (C) Block diagram of pfatp4 gene structure and positioning of mutations
detected in strains resistant to (+)-SJ733. The selected mutations are color-coded to match those in A, with the location in the coding sequence indicated. The
blue cylinders represent the helical portions of the protein shown as blue on the ribbon diagram in A. (D) SJ733 disrupted resting [Na+]i within asexual blood-
stage P. falciparum as illustrated by dose–response experiments with the active (+) and inactive (−) enantiomers. Resting [Na+]i was measured >60 min after
addition of the compound to sodium-binding benzofuran isophthalate-loaded, saponin-isolated parasites. Each data point represents the mean final [Na+]i
averaged from at least three independent experiments (shown ± SD). The relative potencies of the two SJ733 isomers in the [Na+]i assays shown here, on the
two different strains (the SJ733-resistant mutant ATP4L350H and the wild-type parent) matched those seen in parasite growth assays.
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primary growth inhibition effects of (+)-SJ733 stemming from its
ability to increase [Na+]i through inhibition of PfATP4.
Inhibition of Plasmodium ATP4 Leads to Rapid Clearance in Vivo
Through Inducing Physical Changes in Infected, Treated Red Cells.
Treatment of P. falciparum-infected NOD-scid IL2Rγnull mice
(9) with (+)-SJ733 caused rapid clearance of parasites, which
were 80% depleted within the first 24 h and undetectable by 48 h
(Fig. 3A). Notably, (+)-SJ733 cleared parasites faster than
artesunate in the same model. The same pharmacodynamics
were observed after treatment of P. falciparum-infected sple-
nectomized NOD-scid IL2Rγnull mice (Fig. 3B) or normal mice
infected with rodent malarias, with or without liposomal clodr-
onate depletion of Kupffer cells (SI Appendix, Fig. S3A). As
discussed above, although the rate of action remains the same,
the potency of (+)-SJ733 varied by >10-fold between these
models. Thus, the rate of clearance in vivo was independent of
both malaria species and host immune status.
When infected erythrocytes were treated with (+)-SJ733 in vitro,
growth was fully arrested within 24 h, as measured by using lucif-
erase-labeled parasites (Fig. 3C), but fully killing parasites required
96 h (Fig. 3D), as measured by using clonal dilution methods (14).
Given that a typical P. falciparum-infected mouse has ∼108 para-
sites, the same load used in the in vitro cidality assays, it appears
that (+)-SJ733 acts at least fourfold faster in vivo than it does in
vitro. These data suggest that compounds targeting ATP4 induce
physical changes in the infected erythrocyte that allow recognition
and clearance of treated, infected cells by the host.
The most obvious explanation for enhanced clearance in vivo
is that (+)-SJ733 induces an erythrocyte phenotype leading to
rapid clearance such as eryptosis (suicidal erythrocyte death) or
senescence, which can be caused by a wide range of stresses (15,
16). Eryptotic and senescent erythrocytes share several key fea-
tures: an increase in exposed phosphatidylserine (PS), increased
membrane rigidity, more spherical shape, and decreased size (17,
18). The eryptotic/senescent phenotype has been correlated with
increased clearance of erythrocytes, primarily through eryth-
rophagocytosis (19–21). However, mechanical clearance in the
spleen (22) and sinusoidal clearance, independent of Kupffer
cells, in the liver (16) also both play a role and can compensate
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Fig. 3. SJ773 causes rapid clearance in vivo that is not dependent upon innate immunity. (A) (+)-SJ733 causes rapid clearance of parasites in vivo, with speed
equivalent to artesunate, the fastest-acting antimalarial drug, as measured by clonal dilution assays. When total parasites present in blood are measured, all
parasites are cleared systemically within 48 h of initiation of therapy. Similar pharmacodynamics are seen in P. berghei-infected animals (SI Appendix). (B) The in vivo
clearance rate of (+)-SJ733 is independent of the presence of a spleen. When total parasites in blood are measured, all parasites are cleared within 48 h of initiation
of treatment in both splenectomized and nonsplenectomized animals. Similar experiments in clodronate-treated animals infected with P. berghei indicate that
macrophages are not required for rapid pharmacodynamics (SI Appendix). (C) (+)-SJ733 arrests growth of parasites rapidly in vitro, reaching a maximal effect within
24 h as measured by proliferation of a luciferase-labeled 3D7 strain. (D) (+)-SJ733 kills parasites in vitro, but does so withmodest speed, equivalent to pyrimethamine
as measured by clonal dilution assays. When viable parasites are measured, 96 h of continuous exposure above the EC99 is required for maximal effect.
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for a lack of erythrophagocytosis in macrophage-depleted ani-
mals. We simultaneously measured each of these variables for
uninfected and infected erythrocytes in vitro using multimodal
fluorescence activated cell sorting measuring forward/side scatter
(size and shape), parasite infection (SYBR green binding), and
PS exposure (Annexin V binding).
Plasmodium-infected erythrocytes (iRBCs) have been reported
to possess a mild eryptotic/senescent phenotype (23) relative to
uninfected erythrocytes (uRBCs). In our studies iRBCs were
small relative to uRBCs (Fig. 4A, lower forward scatter in Top
Left vs. Bottom Left) and possessed more exposed PS [color scale
in Fig. 4A; uRBCs, green (<1,000 Annexin binding) and iRBCs,
A C
B
D
Fig. 4. SJ733 arrests parasite development and induces eryptosis selectively in infected erythrocytes. (A) (+)-SJ733 causes a significant proportion of infected
erythrocytes to shrink and expose PS. Uninfected erythrocytes, whether treated with (+)-SJ733 or not (Bottom Left and Bottom Right), remain normally sized, do
not have exposed PS, and do not possess substantial DNA, as evidenced by examining the cell population for forward scatter, Annexin V binding, and SYBR
green binding in FACS. Cells are shown as a population contour plot that compared scatter with SYBR green binding and are color-coded to indicate Annexin
binding. After infection, magnetically purified trophozoite/schizont-infected erythrocytes can be detected in three populations (large, with little exposed PS;
small, with moderate levels of exposed PS; and intermediate-sized, with high levels of exposed PS), with the majority being in the small- and large-sized
populations. Treatment with (+)-SJ733 causes the population distribution to shift strongly toward the intermediate-sized population with high amounts of
exposed PS—consistent with strong induction of eryptosis. This shift is not seen with either control drugs or DMSO treatment. (B) When the eryptosis induction
effect is examined for (+)-SJ733 by using a concentration-response experiment, the maximal effect is seen at a concentration of ∼40 nM and the EC50 at 30 nM—
congruent with the doses causing similar levels of response for proliferation inhibition and parasite Na+ levels. Artesunate has no such effect. (C) (+)-SJ733
causes a significant increase in rigidity of infected, treated erythrocytes. As previously reported, infection of erythrocytes (iRBC) causes a significant increase in
their rigidity (P < 0.001; Jonckheere–Terpstra test). After treatment with (+)-SJ733, these infected erythrocytes become significantly more rigid, with the degree
of rigidity peaking at ∼7 h after treatment. *P < 0.001 (Jonckheere–Terpstra test). There are no detectable effects on unparasitized erythrocytes at any time
point. (D) (+)-SJ733 induces a rapid arrest of parasite motility inside infected erythrocytes that is maintained for the period of treatment as shown by time-lapse
microscopy of the treated and untreated cells. The first row of images shows typical motility and growth of a ring-stage parasite over 18 h, which is in stark
contrast to the treated parasite in the second row of images that immediately arrests both motility and growth. In some cases the parasite can be observed to
lyse within the erythrocyte as shown in the third row. In additional cases the infected, treated erythrocyte itself will lyse after lysis of the parasite as shown in
the fourth row. No changes are noted to erythrocyte morphology after treatment of uninfected erythrocytes.
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white to light pink (1,000–5,000 Annexin binding)]. Treatment of
iRBCs with (+)-SJ733, or with another ATP4-targeted compound
(the spiroindolone NITD-246), caused the majority of the cells to
shift to the population with the most severe phenotype possessing
a 10-fold increase in exposed PS relative to uRBCs [Fig. 4A; in-
creased pink intensity (10,000 to >1000,000 Annexin binding,
Middle Left and Middle Right)]. The potency of (+)-SJ733 in
shifting cells from the mild to more severely eryptotic/senescent
phenotype was almost identical to that observed for growth in-
hibition (EC50 30 nM; Fig. 4B). No other class of antimalarial
drug has this profile. For example artesunate, another rapidly
acting drug (Fig. 4A, Top Right) did not produce the more pro-
nounced phenotype, regardless of dose. Importantly, this re-
sponse is dependent upon the presence of both the parasite and
the drug, because treatment of uninfected erythrocytes did not
induce eryptosis (Fig. 4A, Bottom Right).
The biconcave cell shape of RBCs causes a multimodal distri-
bution of forward scatter scores, whereas changing RBC mor-
phology to a more spherical shape characteristic of eryptosis/
senescence leads to a more monomodal distribution (24) that can
be captured by regression modeling of forward and side scatter
data (25). The treatment of iRBCs with (+)-SJ733 (or NITD246)
collapsed the multimodal distribution largely to a monomodal
distribution (containing >85% of cells) of the iRBCs, which when
modeled is similar to spherical cells (MI −0.7) and not to discoid
cells (MI −0.9). This finding suggests that inhibition of ATP4 in the
parasite leads to a spherical morphology, perhaps through parasite
swelling. Individual iRBCs that are more spherical are also ob-
served after treatment with (+)-SJ733 in video microscopy (Fig. 4D,
comparing the first row to the following three). These cell shape
changes were not observed for either uRBCs or untreated iRBCs.
The eryptotic/senescent phenotype also includes an increase in
rigidity as measured by deformation when the cell is pushed
through a capillary with fluid pressure. (+)-SJ733 treatment of
iRBCs caused them to become significantly more rigid compared
with either uRBCs or untreated iRBCs (Fig. 4C; P < 0.001;
Jonckheere–Terpstra test). Again, there was no effect on the
rigidity of uRBCs exposed to (+)-SJ733. This increase in rigidity
was larger in magnitude than previously reported to take place
after infection (26) and is congruent with the magnitude of loss
of deformability that is associated with rapid clearance of eryp-
totic/senescent erythrocytes (17, 27, 28).
Finally, treatment of infected erythrocytes led to the arrest of
parasite development (Fig. 4D, row 2, relative to row 1) and to
changes in the morphology of both the parasite (swelling) and
the erythrocyte (becoming pyknotic) as observed by serial single
cell phase contrast microscopy. All of these changes reached
maximal effect within 1 h of treatment and were maintained for
the duration of treatment—congruent with the time scale on
which [Na+]i increases. In many cases the swelling of the parasite
was followed by parasite bursting (Fig. 4D, row 3) or by se-
quential bursting of the parasite and the infected, treated
erythrocyte (Fig. 4D, row 4). These effects become evident after
7–10 h. In all cases, the effects on erythrocyte morphology and
integrity were limited to treated, infected erythrocytes, with no
changes observed in uninfected, treated erythrocytes.
Together, these data strongly suggest that (+)-SJ733 produces
structural changes in infected erythrocytes consistent with
eryptosis/senescence, while leaving uninfected erythrocytes
unscathed. This effect is clearly not due to simple changes in
erythrocyte ion content; similar (eryptotic) changes were not
seen on treatment of uninfected erythrocytes with the Na+/K+
ATPase inhibitor ouabain under conditions shown previously to
cause major perturbation of the Na+/K+ ratio in the erythrocyte
cytosol (SI Appendix, Fig. S3G) (29). Our data suggest that
eryptosis may be induced by mechanical changes caused by
parasite swelling. Induction of the eryptosis/senescence pheno-
type leads to clearance by several documented mechanisms. Our
results in animals with varying phagocyte and macrophage
defects, as described above, suggest that all of these clearance
mechanisms are used in a complementary way to drive the rapid
clearance of parasites in vivo by (+)-SJ733.
The data presented here are consistent with the model outlined
in Fig. 5. Treatment of parasitized erythrocytes with (+)-SJ733
blocks the normal function of PfATP4 and leads to a rapid increase
of [Na+]i within the parasite, reaching a maximum by 1.5 h after
treatment. This immediate response triggers other cellular respon-
ses, probably including the arrest of protein synthesis (8), and these
are integrated at the level of both the parasite (manifested as a
swollen, development-arrested phenotype) and the host erythrocyte
(manifested as induction of an eryptotic/senescent phenotype).
These morphological changes reach a maximum by 7–8 h after
treatment. In vivo, these effects trigger rapid clearance of the infec-
ted, treated erythrocytes through host-mediatedmechanisms used to
clear aging red cells. Conversely, in vitro, without the physiological
clearance mechanisms, the parasites go into a growth-arrested state,
with maximal arrest being reached by 24 h after treatment. Parasites
1.5
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changes similar to
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Fig. 5. Induction of eryptosis by SJ733 triggers rapid clearance in vivo.
When (+)-SJ733 is added to erythrocytes infected with Plasmodium spp., it
prevents the action of the putative Na+ ATPase PfATP4 and causes a signif-
icant increase in cytosolic Na+ within the parasite, reaching maximal effect
within 90 min after treatment. This process results in the immediate arrest of
parasite motility and blockade of intracellular parasite replication that rea-
ches maximal potency after 24 h of exposure. Simultaneously, infected,
treated erythrocytes begin to enter eryptosis, as characterized by their
shrinking and becoming more spherical, becoming significantly more rigid,
and exposing PS on their plasma membrane. These effects maximize by 7 h
after treatment. In vitro, the drug effects lead to complete arrest of repli-
cation within 24 h of treatment, followed by slow death, which is maximal
by 96 h. In stark contrast to the in vitro setting, the induction of eryptosis
leads to rapid clearance of the infected, treated erythrocytes in vivo.
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then die by a number of mechanisms, including spontaneous lysis,
with the maximal effect ultimately reached within 96 h.
In conclusion, these studies of (+)-SJ733 indicate that PfATP4
inhibitors, including both the DHIQs and the spiroindolones,
possess multiple properties that make them ideal for development
as fast-acting components of combination therapies for single dose
cure of malaria. First, the host-mediated mechanism leads to ex-
tremely rapid clearance in vivo, thus obviating the need for ex-
tended coverage. Indeed, the spiroindolones have proven faster
acting in the clinic than expected from preclinical modeling (30).
Second, they have exquisite selectivity due to a host-mediated
mechanism—only affecting infected and treated erythrocytes.
Third, there is a high fitness cost associated with resistance-con-
ferring mutations. This trait is potentially due to the observed
higher resting [Na+]i causing cellular stress. The combination of
this fitness cost and the extremely rapid action of the compounds
make it very difficult for the parasite to acquire resistance in vivo
despite a frequency of in vitro resistance acquisition that is in line
with other targeted drugs. Therefore, we hypothesize that the
acquisition of resistance during clinical use will occur at a very low
frequency, on par with artemisinin-containing drugs. The rapid in
vivo clearance produced by compounds that target ATP4 make it
an attractive drug development target and the favorable properties
of (+)-SJ733 encourage further development.
Materials and Methods
All procedures were carried out according to published methods. Details of
the methods are included in SI Appendix. The detailed methods included in
SI Appendix are the in vivo efficacy studies for blood stages in both the
P. falciparum and P. berghei models; in vivo transmission blocking studies; in
vivo and in vitro pharmacokinetics studies in all species; in vitro and ex vivo
efficacy studies in P. falciparum and P. berghei; synthesis of (+)-SJ733; ho-
mology modeling and docking studies of (+)-SJ733 binding to PfATP4; in
vitro and in vivo selection of mutant strains of P. falciparum and P. berghei
resistant to (+)-SJ733; whole-genome and Sanger sequencing of mutant
strains; quantitative PCR of mutant strains; production of transgenic para-
sites; measurement of cytosolic Na+ and pH; mutant fitness studies; time-
lapse microscopy studies; erythrocyte rigidity studies; FACS analysis of
erythrocytes; and measurement of speed of effect on P. falciparum. The
SI Appendix includes additional data related to the generation, charac-
terization of the chemical sensitivity, and genotype of P. falciparum
strains resistant to (+)-SJ733; summaries of the in vivo efficacy and
pharmacokinetics data; and the details of safety pharmacology and
tolerability studies.
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